ProMIS Highlights Alzheimer's & Dementia Publication Linking Preferential Targeting Of Soluble Toxic Aβ Oligomers To Efficacy And Lower ARIA Risk

Benzinga · 2d ago
  • Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque 
  • ProMIS on track to complete enrollment in PRECISE-AD trial in Alzheimer's disease by end of 2025 with planned Q2 2026 interim readout